Lebanese Guideline on Good Pharmacovigilance Practices (LGVP)

Announcement – January 30^th, 2026
Public Consultation on New LGVP Modules

The Lebanese Ministry of Public Health (MoPH), through the Lebanese National Pharmacovigilance Program (LNPVP), is pleased to announce the release of two additional modules of the Lebanese Good Pharmacovigilance Practices (LGVP) Guideline for public consultation:

Module III: Pharmacovigilance Inspections
Module IV: Pharmacovigilance Audits

In line with the MoPH’s commitment to transparency, regulatory strengthening, and continuous improvement of pharmacovigilance systems in Lebanon, all Marketing Authorization Holders (MAHs) and stakeholders involved in pharmacovigilance activities are invited to review these modules and submit their comments, suggestions, or questions.

Public Consultation Period
February 1st to April 30th, 2026

How to Participate

The modules are available under the relevant section of the Lebanese National Pharmacovigilance Program webpage.
Proposals for corrections, revisions, or additions should be submitted using the official Excel consultation template provided below.

Comments should be sent within the consultation period to the following email addresses:
lgvp@moph.gov.lb
lgvp.moph@gmail.com

Each Excel file should be named according to the following convention:
“Module [Module Number] – [Company Name].xls”
(e.g., Module III – CompanyName.xls)

An acknowledgment email will be sent to confirm receipt of the submitted comments.

Important Clarification
To ensure appropriate follow-up, the following reviewer details must be included in the body of the submission email:
Reviewer’s full name
Reviewer’s contact information (email and phone number)
Reviewer’s current country of residence

For further information or inquiries, please contact the Pharmacovigilance Team through the above email addresses.

The Lebanese Ministry of Public Health extends its sincere appreciation to all stakeholders for their continued collaboration and active participation in strengthening pharmacovigilance and medication safety in Lebanon.

Announcement – Date: January 15th , 2026:

We are pleased to announce the publication of the finalized versions of LGVP Modules I, II, V, VI, VII, VIII, XV and XVI, together with the introductory note and definitions.

Announcement – Date: January 31th, 2023
We are pleased to announce the extension to LGVP public consultation deadlines.
Phase II (Modules II, V, and XVI): Extended from February 16th, 2024 to March 16th, 2024.
Phase III (Modules VII, VIII, and XV): Extended from March 16th, 2024 to April 16th, 2024.
 

• Reviewer's full name 
• Reviewer's contact information, including phone number and email 
• Reviewer's current country of residence 

Beirut, October 16, 2023 — The Lebanese Ministry of Public Health (MoPH) is pleased to announce the official release of Version 1 of the Lebanese Good Pharmacovigilance Practices Guideline (LGVP) for public consultation.
In alignment with our commitment to transparency, safety, and continuous improvement, we invite all Marketing Authorization Holders and any party or individual involved in pharmacovigilance activities in Lebanon to actively participate in the public consultation phase for this guideline. Your valuable input, comments, and questions will contribute to the refinement of the guideline.

 

Guideline Overview:
The LGVP outlines essential standards and best practices in pharmacovigilance, ensuring that all pharmaceutical products available in Lebanon meet the highest safety and quality standards. This guideline will play a pivotal role in strengthening our nation's pharmaceutical sector and, most importantly, safeguarding public health.

 

Public Consultation Details:
The public consultation period will follow a sequential release of Modules to be organized into three distinct phases, each extending for a duration of three months, with a one-month interval between phases. These phases are outlined as follows:

 

As of the date of the present announcement, the MoPH is proud to initiate Phase I of the public consultation for the concerned Modules.
 
How to Participate:
To access the guideline and participate in the public consultation, kindly access the links for the Modules provided under the relevant section of the present Lebanese National Pharmacovigilance Program webpage.

Proposals for corrections, revision, or addition suggested to any section of the released Modules are to be shared through the provided link for the Excel sheet and sent to both of the following emails within the specified timeframe: lgvp@moph.gov.lb, and lgvp.moph@gmail.com.

We kindly request that you use the provided Excel sheet for each respective Module. The Excel file should be named according to the following convention: “Module [Module number]-[Company name].xls”, for instance, "Module I-Mersaco.xls." Your compliance with this naming convention is greatly appreciated.

An acknowledgment email will be sent to confirm the receipt pf the suggested comments.

For further information and inquiries, please contact the Pharmacovigilance Team through the above email.